Evidence map›Paper›PMID 42148102›Full record

ArticleFrontiers in immunology2026

Liangliang Weng, Zhang Huijie, Ni Man, Liu Yang, Min Cao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Liangliang WengDepartment of Infectious Diseases, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang, China.
Zhang HuijieThe Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Ni ManThe Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Liu YangThe Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Min CaoDepartment of Nursing, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: An integrated reverse vaccinology and experimental validation approach was employed to design a multi-epitope vaccine against Results: The vaccine candidate exhibited favorable physicochemical properties, structural stability, and strong binding affinity toward Toll-like receptor 2. In silico immune simulations predicted robust Th1-biased immune responses with effective memory formation. Recombinant expression yielded a soluble, monodisperse protein. Functional assays demonstrated significant inhibition of Conclusion: The proposed multi-epitope vaccine candidate induces coordinated innate and adaptive immune responses and exhibits promising antibacterial activity against

Indexed as

Bacterial VaccinesEpitopes, B-LymphocyteEpitopes, T-LymphocyteHelicobacter hepaticusHelicobacter InfectionsHepatitisAnimalsComputer SimulationEpitope MappingFemaleHumansImmunoinformaticsMiceMolecular Docking SimulationMolecular Dynamics SimulationProtein Subunit VaccinesBacterial VaccinesEpitopes, B-LymphocyteEpitopes, T-LymphocyteProtein Subunit Vaccinescellular immunityHelicobacter hepaticusimmunoinformaticsmulti-epitope vaccine candidatereverse vaccinologystructural vaccinologytoll-like receptor 2

Identifiers

PMID42148102
PMCPMC13171813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.